|
Search concepts
|
|
Selected Filters
|
Search results
-
Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks
5/20/20 → 5/21/20
26 items of Media coverage
Press/Media: Expert Comment
-
Preclinical research - Reveals new IgM antibodies administered intranasally to fight COVID-19 more potent than commonly used ones
Xuping Xie, Pei-Yong Shi & Vineet Menachery
6/22/21
1 item of Media coverage
Press/Media: Expert Comment
-
University of Texas Medical Branch Has Developed New System for Combatting COVID-19 That Can Be Used for Other Viruses
Shinji Makino, Benny Raimer, Xuping Xie, Kenneth Plante, Patricia Aguilar & Vineet Menachery
4/7/20
1 item of Media coverage
Press/Media: Expert Comment
-
ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib
John Manning, Cheng Huang & Slobodan Paessler
5/20/20
18 items of Media coverage
Press/Media: Expert Comment
-
Preclinical research reveals that new IgM antibodies administered intranasally to fight COVID-19 more potent than commonly used ones
Xuping Xie, Pei-Yong Shi & Vineet Menachery
6/3/21
6 items of Media coverage
Press/Media: Expert Comment
-
ViralClear Adds St. David's HealthCare In Austin, Texas, To Its Planned Phase II Trial For Its Broad-Spectrum Oral Anti-Viral Candidate For COVID-19
John Manning, Cheng Huang & Slobodan Paessler
6/5/20
25 items of Media coverage
Press/Media: Expert Comment
-
Sorrento and The University of Texas medical branch at Galveston enter into preclinical testing agreement for COVID-19 therapeutic candidates
Cheng Huang & Slobodan Paessler
3/31/20 → 4/1/20
2 items of Media coverage
Press/Media: Expert Comment
-
Sorrento Therapeutics And ViralClear Enter Into Agreement To Explore Combination Antibody Plus Antiviral Therapy Against COVID-19
John Manning, Cheng Huang & Slobodan Paessler
9/30/20
19 items of Media coverage
Press/Media: Expert Comment
-
BioSig Technologies: ViralClear Closes $10.8 Million Equity Financing for Development of COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib
John Manning, Cheng Huang & Slobodan Paessler
5/20/20
1 item of Media coverage
Press/Media: Expert Comment
-
ViralClear Publishes Comparative In Vitro Data On Merimepodib And Remdesivir Activity Against The COVID-19 Novel Coronavirus In F1000 Research
John Manning, Cheng Huang & Slobodan Paessler
4/23/20
17 items of Media coverage
Press/Media: Expert Comment
-
SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES
Cheng Huang & Slobodan Paessler
3/31/20
24 items of Media coverage
Press/Media: Expert Comment
-
SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19
John Manning, Cheng Huang & Slobodan Paessler
9/30/20
21 items of Media coverage
Press/Media: Expert Comment
-
ViralClear Submits In Vitro Data On Merimepodib And Remdesivir Synergistic Activity Against The COVID-19 Novel Coronavirus To A Peer-Reviewed Journal
John Manning, Cheng Huang & Slobodan Paessler
4/30/20
18 items of Media coverage
Press/Media: Expert Comment
-
ViralClear Publishes Comparative In Vitro Data on Merimepodib and Remdesivir Activity Against the COVID-19 Novel Coronavirus in F1000 Research Nasdaq:BSGM
John Manning, Cheng Huang & Slobodan Paessler
4/23/20
1 item of Media coverage
Press/Media: Expert Comment
-
Scientists Worldwide Feverishly Working to Develop New Drug and Vaccine Candidates for COVID-19 Crisis; Financialnewsmedia.com News Commentary
John Manning, Cheng Huang & Slobodan Paessler
4/23/20
1 item of Media coverage
Press/Media: Expert Comment
-
Advances in COVID-19 Testing, Artificial Intelligence, Cancer Therapies, and The Future of Precision Medicine to Be Explored at The All-Virtual 2020 AACC Annual Scientific Meeting
12/13/20 → 12/14/20
22 items of Media coverage
Press/Media: Expert Comment
-
Advances In COVID-19 Testing, Artificial Intelligence, Cancer Therapies, And The Future Of Precision Medicine To Be Explored At The All-Virtual 2020 AACC Annual Scientific Meeting
12/13/20 → 12/14/20
3 items of Media coverage
Press/Media: Expert Comment
-
FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear's Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed Nasdaq:BSGM
John Manning, Cheng Huang & Slobodan Paessler
5/18/20
13 items of Media coverage
Press/Media: Expert Comment
-
ViralClear To Host Conference Call On June 9th To Discuss Upcoming And Recent Developments For Phase II Human Clinical Trials Of Its Broad-Spectrum Oral Anti-viral Candidate For Treatment Of COVID-19
John Manning, Cheng Huang & Slobodan Paessler
6/1/20
14 items of Media coverage
Press/Media: Expert Comment
-
ADVANCES IN COVID-19 TESTING, ARTIFICIAL INTELLIGENCE, CANCER THERAPIES, AND THE FUTURE OF PRECISION MEDICINE TO BE EXPLORED AT THE ALL-VIRTUAL 2020 AACC ANNUAL SCIENTIFIC MEETING | DEC.13.2020
12/13/20
1 item of Media coverage
Press/Media: Expert Comment
-
ViralClear Pharmaceuticals Partners with Albany Molecular Research on the Manufacture of Merimepodib Active Pharmaceutical Ingredient in Development for the Potential Treatment of COVID-19
John Manning, Cheng Huang & Slobodan Paessler
7/8/20
3 items of Media coverage
Press/Media: Expert Comment
-
ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19 Nasdaq:BSGM
John Manning, Cheng Huang & Slobodan Paessler
7/8/20
2 items of Media coverage
Press/Media: Expert Comment
-
ViralClear Pharmaceuticals Partners With Albany Molecular Research (AMRI) on the Manufacture of Merimepodib Active Pharmaceutical Ingredient in Development for the Potential Treatment of COVID-19
John Manning, Cheng Huang & Slobodan Paessler
7/8/20
2 items of Media coverage
Press/Media: Expert Comment
-
ViralClear Pharmaceuticals Partners With Albany Molecular Research Inc. On The Manufacture Of Merimepodib Active Pharmaceutical Ingredient Development For The Potential Treatment Of COVID-19
John Manning, Cheng Huang & Slobodan Paessler
7/7/20 → 7/8/20
16 items of Media coverage
Press/Media: Expert Comment
-
BioSig Technologies: FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear's Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed
John Manning, Cheng Huang & Slobodan Paessler
5/18/20
1 item of Media coverage
Press/Media: Expert Comment